ARTICLE | Finance
Ebb & Flow
January 28, 2008 8:00 AM UTC
Despite three analyst upgrades, Human Genome Sciences (NASDAQ:HGSI) ended last week down $4.61 (44%) to $5.86 after an independent DMC raised safety concerns about the higher dose in two Phase III trials of Albuferon albumin-interferon alpha to treat HCV.
The decline trimmed the company's market cap to $789 million from $1.4 billion. On Wednesday, the day of the announcement, HGS fell $4.40 (44%) to $5.62. ...